HOOK - Hookipa posts positive preclinical data from arenaviral HIV therapeutic vaccines trial

Hookipa Pharma (NASDAQ:HOOK) on Friday announced positive preclinical data from arenaviral therapeutic vaccines that are being studied as a component of a potential functional curative regimen for HIV.  (HOOK) up ~2% before the bell. The studies are being done in collaboration with Gilead Sciences (GILD). The company said the analyses were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as an analog to HIV. The study showed both single-vector and alternating 2-vector therapy induced robust antigen-specific T cell and antibody responses in nonhuman primates. The data were presented at the Keystone Symposium, titled Progress in Vaccine Development for Infectious Disease.

For further details see:

Hookipa posts positive preclinical data from arenaviral HIV therapeutic vaccines trial